About the company
MDxHealth SA is a leading multinational healthcare company that revolutionizes cancer diagnosis and treatment through the provision of actionable molecular diagnostic information. With its innovative tests, MDxHealth helps physicians personalize the diagnosis and treatment of cancer, ultimately leading to better patient outcomes. The core of MDxHealth's tests lies in its proprietary genomic, epigenetic, and other molecular technologies. These advanced techniques enable the company to analyze specific biomarkers and genetic mutations associated with different types of cancer, particularly urologic cancers. By examining the unique molecular profiles of tumors, MDxHealth's tests offer invaluable insights into the prognosis, recurrence risk, and potential response to treatment for each individual patient. The company's DNA methylation platform serves as the foundation for its tests. DNA methylation is an essential epigenetic modification that plays a crucial role in gene regulation. MDxHealth's patented platform allows for the accurate and sensitive detection of changes in DNA methylation patterns that are indicative of cancer development and progression. By leveraging this cutting-edge technology, MDxHealth's tests can provide physicians with highly precise and reliable information about a patient's cancer characteristics. MDxHealth's business model encompasses both clinical laboratory service testing and the out-licensing of its patented DNA methylation platform and biomarkers. Through its clinical laboratory services, the company performs the necessary tests and provides physicians with comprehensive reports that aid in the diagnosis and treatment decision-making process. This revenue stream ensures that MDxHealth remains at the forefront of cancer diagnostics, consistently advancing its technologies and expanding its test portfolio. Additionally, MDxHealth generates revenue by licensing its proprietary DNA methylation platform and biomarkers to other healthcare organizations and diagnostic laboratories. This strategic approach enables the company to extend its reach globally, as it collaborates with partners who can implement MDxHealth's technology in various healthcare settings across the United States of America (USA), and Europe. While MDxHealth is headquartered in Europe, its presence extends far beyond the borders of the continent. The company generates a significant portion of its revenue from the USA, where it has established a strong foothold in the molecular diagnostics market. With the high prevalence of cancer and the growing demand for personalized medicine in the USA, MDxHealth is well-positioned to continue expanding its market share and cement its status as a leader in molecular diagnostics. In Europe, MDxHealth operates across various countries, working closely with healthcare providers to integrate its innovative tests into the standard cancer diagnostic and treatment protocols. Through strategic partnerships and collaborations, the company ensures that its cutting-edge technologies reach patients and healthcare professionals throughout the continent, enhancing the accuracy and effectiveness of cancer care. As MDxHealth continues to pioneer advancements in molecular diagnostics, it remains dedicated to transforming cancer management globally. With its actionable molecular diagnostic information, the company is enabling physicians to deliver personalized care that maximizes patient outcomes. By harnessing the power of proprietary genomic, epigenetic, and molecular technologies, MDxHealth is revolutionizing cancer diagnosis and treatment, providing hope and improve the quality of life for countless individuals affected by this devastating disease.
Data updated: April 10, 2026
